News
NewAmsterdam Pharma Company NV
NAMS · NASDAQ
$21.50+$1.03 (+5.03%)TodayMarket closed ·
Prev close $20.47
Latest news
- Press releaseGlobe Newswire
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- NewsAvi Kapoor
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
- Press releaseGlobe Newswire
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
- Press releaseGlobe Newswire
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- Press releaseGlobe Newswire
Attovia Therapeutics Appoints John W. Smither to Board of Directors
- NewsAvi Kapoor
Monster Beverage, Westrock Coffee, Himax Technologies And Other Big Stocks Moving Higher On Friday
- Press releaseGlobe Newswire
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
- News
Forecasting The Future: 4 Analyst Projections For NewAmsterdam Pharma Co
- News
Earnings Summary: NewAmsterdam Pharma Co Q4
- Press releaseGlobe Newswire
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
- News
Assessing NewAmsterdam Pharma Co: Insights From 5 Financial Analysts
- Press releaseGlobe Newswire
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
- Press releaseGlobe Newswire
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
- News
Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings)
- Press releasePRNewswire
Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to Measure Coronary Plaque and Inflammation
- News
Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts
- Press releasePRNewswire
Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
- Press releaseGlobe Newswire
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
- News
What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co
- Press releaseBusiness Wire
Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
- News
'Biotech Says Its Cholesterol Drug Shows Signs Of Preventing Alzheimer's; NewAmsterdam Pharma Hopes Medicine Born Out Of Big Failures May Have An Unexpected Benefit' - STAT News
- News
What Analysts Are Saying About NewAmsterdam Pharma Co Stock
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts
- NewsAvi Kapoor
Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
- Press releasePRNewswire
Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg
- NewsLekha Gupta
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
- NewsAvi Kapoor
Top 3 Health Care Stocks That May Collapse This Quarter
- News
Forecasting The Future: 5 Analyst Projections For NewAmsterdam Pharma
- Press releaseBusiness Wire
Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors
- News
What 4 Analyst Ratings Have To Say About NewAmsterdam Pharma
- News
Expert Ratings For NewAmsterdam Pharma
- NewsVandana Singh
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside
- Press releasePRNewswire
Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
- Press releasePRNewswire
Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.